Geometric expansion for radiation treatment in nasopharyngeal carcinoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This phase III clinical trial evaluates the efficacy and safety of modified intensity-modulated radiation therapy (IMRT) for newly diagnosed nasopharyngeal carcinoma patients without distant metastasis. Patients will be randomly assigned to receive either a geometric expansion-based delineation of the clinical target volume (CTV) or a standard approach based on established guidelines. The trial aims to determine if the geometric expansion method can provide effective treatment outcomes while potentially reducing radiation exposure to surrounding healthy tissues. The study will involve multiple centers and will adhere to international guidelines for target area definitions.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Pathologic diagnosis (pathologically confirmed by nasopharyngeal biopsy) was nasopharyngeal carcinoma;
2. No distant metastatic;
3. Patients with baseline MRI date of nasopharynx and neck, and completed the first course of treatment in our hospital;
4. Eastern Cooperative Oncology Group (ECOG) score of 0 or 1;
5. Signing informed consent;
6. Follow up regularly and comply with test requirements.

Exclusion Criteria:

1. Disease progression during IMRT;
2. Previous malignancy or other concomitant malignant diseases;
3. The evaluation information of tumor efficacy can not be obtained;
4. Receive blind treatment in other clinical research;
5. Have or are suffering from other malignant tumors within 5 years (except non- melanoma skin cancer or pre-invasive cervical cancer);
6. Serious complications, such as uncontrolled hypertension, coronary heart disease, diabetes, heart failure, etc;
7. Active systemic infection;
8. No or limited capacity for civil conduct;
9. The patient has a physical or mental disorder, and the researcher considers that the patient is unable to fully or fully understand the possible complications of this study;
10. Pregnancy or lactation period;

Where it's running

• Fujian Cancer hospital
  Fuzhou, Fujian, China Recruiting

Study contacts

• Study coordinator: Shaojun Lin, DR
• Email: linshaojun@yeah.net
• Phone: 13860603879

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Nimotuzumab with toripalimab plus gemcitabine/cisplatin for first-line recurrent or metastatic nasopharyngeal carcinoma

  This trial tests whether adding nimotuzumab to toripalimab with gemcitabine and cisplatin helps people with first-line recurrent or metastatic nasopharyngeal carcinoma.

  Recruiting Phase 2 Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing, Beijing Municipality · NCT06509009

• Nimotuzumab combined with chemotherapy and radiation for advanced nasopharyngeal cancer

  This study is testing if adding a new drug called nimotuzumab to chemotherapy and radiation can help people with advanced nasopharyngeal cancer feel better and improve their treatment outcomes.

  Recruiting at 9 sites Fourth Affiliated Hospital of Guangxi Medical University · Baise City, Guangxi and 8 other locations · NCT05717790

• Autologous tumor membrane vesicle (TMV) vaccine alone or with pembrolizumab for recurrent or metastatic head and neck squamous cell carcinoma

  This trial tests whether a vaccine made from a patient's own tumor (TMV), given alone or with pembrolizumab, can help people with recurrent or metastatic head and neck squamous cell carcinoma who had tumor tissue banked at surgery.

  Recruiting at 2 sites Phase 1 Emory University · Atlanta, Georgia and 1 other locations · NCT06868433

• Remote hearing tests for patients with head and neck cancer receiving chemotherapy or radiation

  This study is testing if remote hearing tests can help patients with advanced head and neck cancer keep track of their hearing loss during chemotherapy or radiation, making it easier for those who live far away to participate.

  Recruiting Emory University · Atlanta, Georgia · NCT06662058

• Combining lovastatin and pembrolizumab for advanced head and neck cancer treatment

  This study is testing if combining a cholesterol-lowering drug called lovastatin with an immunotherapy drug called pembrolizumab can help people with advanced head and neck cancer feel better and live longer.

  Recruiting at 2 sites Phase 2 Emory University · Atlanta, Georgia and 1 other locations · NCT06636734

• Using nivolumab with chemotherapy to treat nasopharyngeal carcinoma in young patients

  This study is testing if combining nivolumab with chemotherapy can help young patients with nasopharyngeal carcinoma live longer and feel better while reducing side effects from radiation.

  Recruiting at 84 sites Phase 2 National Cancer Institute (NCI) · Birmingham, Alabama and 85 other locations · NCT06064097

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.